Abstract 217: PCSK9 Inhibitor Use and Health Characteristics Among High-Risk Patients with Atherosclerotic Cardiovascular Disease

Introduction: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are a promising class of lipid lowering therapy. The number of high-risk atherosclerotic cardiovascular disease (ASCVD) patients who may benefit from PCSK9i therapy, and the number of these patients actually initiated on PCSK9i therapy, has not been well characterized. Methods: We used administrative claims from a large, national commercial payer (n=15 million annual covered lives) during years 2015-2016, including inpatient and outpatient facility and provider claims, pharmacy claims, and laboratory results to determine the total number of ASCVD patients ages 18 to 64 years who were adherent to high-intensity statins with persistently high low-density lipoprotein cholesterol (LDL-C), and the fraction of these patients who were subsequently started on a PCSK9i. Secondary objectives were to compare differences in cardiovascular comorbidities, use and adherence to lipid lowering therapies, and baseline LDL-C measurements between...